Update on latex allergy: New insights into an old problem

Làtex; Gestió; A nivell mundialLatex; Management; WordwideLátex; Gestión; A nivel mundialDespite the efforts made to mitigate the consequences of this disease, natural rubber latex allergy (NRLA) continues to be a global health problem and is still considered one of the main worries in the working environment in many countries throughout the world. Due to thousands of products containing latex, it is not surprising that the current statistics suggest that prevalence remains high among healthcare workers and susceptible patients. In developed countries, reduction in the prevalence of IgE-mediated allergy to latex proteins from gloves may lead to lax attention by health care personnel. On the other hand, this situation is different in developing countries where there is a lack of epidemiological data associated with a deficit in education and awareness of this issue. The aim of this review is to provide an update of the current knowledge and practical recommendations regarding NRLA by allergologists from different parts of the world with experience in this field.The authors have not received any funding to prepare the manuscript

Time-resolved molecular dynamics of single and double hydrogen migration in ethanol

Being the lightest, most mobile atom that exists, hydrogen plays an important role in the chemistry of hydrocarbons, proteins and peptides and most biomolecules. Hydrogen can undergo transfer, exchange and migration processes, having considerable impact on the chemical behavior of these molecules. Although much has been learned about reaction dynamics involving one hydrogen atom, less is known about those processes where two or more hydrogen atoms participate. Here we show that single and double hydrogen migrations occurring in ethanol cations and dications take place within a few hundred fs to ps, using a 3D imaging and laser pump-probe technique. For double hydrogen migration, the hydrogens are not correlated, with the second hydrogen migration promoting the breakup of the C–O bond. The probability of double hydrogen migration is quite significant, suggesting that double hydrogen migration plays a more important role than generally assumed. The conclusions are supported by state-of-the-art molecular dynamics calculationsThis work was funded by the National Science Foundation under award No. 1700551, the MINECO projects FIS2016-77889-R and CTQ2016- 76061-P, ‘Severo Ochoa’ Programme for Centres of Excellence in R&D (SEV-2016-0686) and ‘María de Maeztu’ Programme for Units of Excellence in R&D (MDM-2014-0377). We acknowledge the generous allocation of computer time at the Centro de Computación Científica at the Universidad Autónoma de Madrid (CCC-UAM). S.D.-T. gratefully acknowledges the “Ramón y Cajal” program (RYC-2010-07019) of the Spanish Ministerio de Educación y Cienci

Administration route effect on the absorption kinetic of the ricobendazole in sheep

Se estudió el comportamiento farmacocinético del ricobendazole (RBZ) tras su administración intravenosa (i.v), intrarruminal (i.r) y subcutánea (s.c) en ovinos. El RBZ se administró como solución experimental al 10% por la vía i.v, como suspensión experimental al 10% por vía i.r y por vía s.c como solución comercial al 10% (Sintyotal-R®). En todos los casos la dosis administrada fue 5 mg.kg-1. Los datos de concentración plasmática fueron analizados mediante el método no compartimental y la discriminación del orden y la magnitud del proceso de absorción tras la administración i.r se realizó por construcción de curvas de cantidades acumulativas de fármaco ingresado a la circulación general mediante el método de Loo-Riegelman. Tras su administración i.r, el orden de absorción se asimiló a un proceso de orden cero, pero la fracción de la dosis biodisponible fue de alrededor del 30% mientras que tras su administración s.c el RBZ se absorbió rápidamente y casi en su totalidad. Estos resultados muestran un mejor comportamiento farmacocinético de la formulación inyectable con respecto a la clásica suspensión administrada por la vía i.r.The pharmacokinetic behavior of ricobendazole (RBZ) was studied after its intravenous (i.v), intrarruminal (i.r) and subcutaneous (s.c) administration in sheep. Ricobendazole was administered as experimental 10 % solution by i.v route, as experimental 10 % suspension by i.r route and by s.c route as 10% commercial solution (Sintyotal-R®). In all the cases the administered dose was 5 mg.kg-1. The plasma concentration profiles were analyzed by means non-compartmental methodology, and the discrimination of the rate and the order of absorption after i.r administration were performed by construction of cumulative curves of drug entered into the general circulation by means of the Loo-Riegelman method. After i.r administration the order of absorption was best explained as a zero order process, the bioavailability being around 30 %, while after s.c administration t RBZ absorption was fast and bioavailability almost complete. These results shown a best pharmacokinetic behavior of the injectable formulation in comparison with the classic suspension administered by i.r route.Facultad de Ciencias Veterinaria

Administration route effect on the absorption kinetic of the ricobendazole in sheep

Se estudió el comportamiento farmacocinético del ricobendazole (RBZ) tras su administración intravenosa (i.v), intrarruminal (i.r) y subcutánea (s.c) en ovinos. El RBZ se administró como solución experimental al 10% por la vía i.v, como suspensión experimental al 10% por vía i.r y por vía s.c como solución comercial al 10% (Sintyotal-R®). En todos los casos la dosis administrada fue 5 mg.kg-1. Los datos de concentración plasmática fueron analizados mediante el método no compartimental y la discriminación del orden y la magnitud del proceso de absorción tras la administración i.r se realizó por construcción de curvas de cantidades acumulativas de fármaco ingresado a la circulación general mediante el método de Loo-Riegelman. Tras su administración i.r, el orden de absorción se asimiló a un proceso de orden cero, pero la fracción de la dosis biodisponible fue de alrededor del 30% mientras que tras su administración s.c el RBZ se absorbió rápidamente y casi en su totalidad. Estos resultados muestran un mejor comportamiento farmacocinético de la formulación inyectable con respecto a la clásica suspensión administrada por la vía i.r.The pharmacokinetic behavior of ricobendazole (RBZ) was studied after its intravenous (i.v), intrarruminal (i.r) and subcutaneous (s.c) administration in sheep. Ricobendazole was administered as experimental 10 % solution by i.v route, as experimental 10 % suspension by i.r route and by s.c route as 10% commercial solution (Sintyotal-R®). In all the cases the administered dose was 5 mg.kg-1. The plasma concentration profiles were analyzed by means non-compartmental methodology, and the discrimination of the rate and the order of absorption after i.r administration were performed by construction of cumulative curves of drug entered into the general circulation by means of the Loo-Riegelman method. After i.r administration the order of absorption was best explained as a zero order process, the bioavailability being around 30 %, while after s.c administration t RBZ absorption was fast and bioavailability almost complete. These results shown a best pharmacokinetic behavior of the injectable formulation in comparison with the classic suspension administered by i.r route.Facultad de Ciencias Veterinaria

IceCube Search for Neutrinos Coincident with Compact Binary Mergers from LIGO-Virgo's First Gravitational-Wave Transient Catalog

Using the IceCube Neutrino Observatory, we search for high-energy neutrino emission coincident with compact binary mergers observed by the LIGO and Virgo gravitational wave (GW) detectors during their first and second observing runs. We present results from two searches targeting emission coincident with the sky localization of each gravitational wave event within a 1000 second time window centered around the reported merger time. One search uses a model-independent unbinned maximum likelihood analysis, which uses neutrino data from IceCube to search for point-like neutrino sources consistent with the sky localization of GW events. The other uses the Low-Latency Algorithm for Multi-messenger Astrophysics, which incorporates astrophysical priors through a Bayesian framework and includes LIGO-Virgo detector characteristics to determine the association between the GW source and the neutrinos. No significant neutrino coincidence is seen by either search during the first two observing runs of the LIGO-Virgo detectors. We set upper limits on the time-integrated neutrino emission within the 1000 second window for each of the 11 GW events. These limits range from 0.02-0.7 $\mathrm{GeV~cm^{-2}}$. We also set limits on the total isotropic equivalent energy, $E_{\mathrm{iso}}$, emitted in high-energy neutrinos by each GW event. These limits range from 1.7 $\times$ 10$^{51}$ - 1.8 $\times$ 10$^{55}$ erg. We conclude with an outlook for LIGO-Virgo observing run O3, during which both analyses are running in real time

Characteristics of the diffuse astrophysical electron and tau neutrino flux with six years of IceCube high energy cascade data

We report on the first measurement of the astrophysical neutrino flux using particle showers (cascades) in IceCube data from 2010 -- 2015. Assuming standard oscillations, the astrophysical neutrinos in this dedicated cascade sample are dominated ($\sim 90 \%$) by electron and tau flavors. The flux, observed in the sensitive energy range from $16\,\mathrm{TeV}$ to $2.6\,\mathrm{PeV}$, is consistent with a single power-law model as expected from Fermi-type acceleration of high energy particles at astrophysical sources. We find the flux spectral index to be $\gamma=2.53\pm0.07$ and a flux normalization for each neutrino flavor of $\phi_{astro} = 1.66^{+0.25}_{-0.27}$ at $E_{0} = 100\, \mathrm{TeV}$, in agreement with IceCube's complementary muon neutrino results and with all-neutrino flavor fit results. In the measured energy range we reject spectral indices $\gamma\leq2.28$ at $\ge3\sigma$ significance level. Due to high neutrino energy resolution and low atmospheric neutrino backgrounds, this analysis provides the most detailed characterization of the neutrino flux at energies below $\sim100\,{\rm{TeV}}$ compared to previous IceCube results. Results from fits assuming more complex neutrino flux models suggest a flux softening at high energies and a flux hardening at low energies (p-value $\ge 0.06$). The sizable and smooth flux measured below $\sim 100\,{\rm{TeV}}$ remains a puzzle. In order to not violate the isotropic diffuse gamma-ray background as measured by the Fermi-LAT, it suggests the existence of astrophysical neutrino sources characterized by dense environments which are opaque to gamma-rays.Comment: 4 figures, 4 tables, includes supplementary materia

Multimessenger Gamma-Ray and Neutrino Coincidence Alerts using HAWC and IceCube sub-threshold Data

The High Altitude Water Cherenkov (HAWC) and IceCube observatories, through the Astrophysical Multimessenger Observatory Network (AMON) framework, have developed a multimessenger joint search for extragalactic astrophysical sources. This analysis looks for sources that emit both cosmic neutrinos and gamma rays that are produced in photo-hadronic or hadronic interactions. The AMON system is running continuously, receiving sub-threshold data (i.e. data that is not suited on its own to do astrophysical searches) from HAWC and IceCube, and combining them in real-time. We present here the analysis algorithm, as well as results from archival data collected between June 2015 and August 2018, with a total live-time of 3.0 years. During this period we found two coincident events that have a false alarm rate (FAR) of $<1$ coincidence per year, consistent with the background expectations. The real-time implementation of the analysis in the AMON system began on November 20th, 2019, and issues alerts to the community through the Gamma-ray Coordinates Network with a FAR threshold of $<4$ coincidences per year.Comment: 14 pages, 5 figures, 3 table

Seguridad de las drogas biológicas y sintéticas dirigidas utilizadas en pacientes con enfermedades reumáticas inmunomediadas. Datos del registro BIOBADASAR 3.0

Introducción: conocer la seguridad de las drogas actualmente disponibles para el tratamiento de las enfermedades reumáticas es muy importante al momento de tomar decisiones terapéuticas objetivas e individualizadas en la consulta médica diaria. Asimismo, datos de la vida real amplían el conocimiento revelado por los ensayos clínicos. Objetivos: describir los eventos adversos (EA) reportados, estimar su frecuencia e identificar los factores relacionados con su desarrollo. Materiales y métodos: se utilizaron datos BIOBADASAR, un registro voluntario y prospectivo de seguimiento de EA de tratamientos biológicos y sintéticos dirigidos en pacientes con enfermedades reumáticas inmunomediadas. Los pacientes son seguidos hasta la muerte, pérdida de seguimiento o retiro del consentimiento informado. Para este análisis se extrajeron datos recopilados hasta el 31 de enero de 2023. Resultados: se incluyó un total de 6253 pacientes, los cuales aportaron 9533 ciclos de tratamiento, incluyendo 3647 (38,3%) ciclos sin drogas modificadoras de la enfermedad biológicas y sintéticas dirigidas (DME-b/sd) y 5886 (61,7%) con DME-b/sd. Dentro de estos últimos, los más utilizados fueron los inhibidores de TNF y abatacept. Se reportaron 5890 EA en un total de 2701 tratamientos (844 y 1857 sin y con DME-b/sd, respectivamente), con una incidencia de 53,9 eventos cada 1000 pacientes/año (IC 95% 51,9-55,9). La misma fue mayor en los ciclos con DME-b/sd (71,1 eventos cada 1000 pacientes/año, IC 95% 70,7-77,5 versus 33,7, IC 95% 31,5-36,1; p<0,001). Las infecciones, particularmente las de la vía aérea superior, fueron los EA más frecuentes en ambos grupos. El 10,9% fue serio y el 1,1% provocó la muerte del paciente. El 18,7% de los ciclos con DME-b/sd fue discontinuado a causa de un EA, significativamente mayor a lo reportado en el otro grupo (11,5%; p<0,001). En el análisis ajustado, las DME-b/sd se asociaron a mayor riesgo de presentar al menos un EA (HR 1,82, IC 95% 1,64-1,96). De igual manera, la mayor edad, el mayor tiempo de evolución, el antecedente de enfermedad pulmonar obstructiva crónica, el diagnóstico de lupus eritematoso sistémico y el uso de corticoides se asociaron a mayor riesgo de EA. Conclusiones: la incidencia de EA fue significativamente superior durante los ciclos de tratamientos que incluían DME-b/sd